Evidence map›Paper›PMID 34146382›Full record

ArticleMolecular oncology2022

Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.

Kang Wang, Lun Li, Sebastià Franch-Expósito, Xin Le, Jun Tang, Qing Li, Qianxue Wu, Laia Bassaganyas, Jordi Camps, Xiang Zhang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Kang WangDepartment of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, China.ORCID 0000-0001-5401-1803
Lun LiDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, China.
Sebastià Franch-ExpósitoGastrointestinal and Pancreatic Oncology Team, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Spain.
Xin LeKey Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, China.
Jun TangKey Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, China.
Qing LiDepartment of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, China.
Qianxue WuDepartment of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, China.
Laia BassaganyasLiver Cancer Translational Research Group, Liver Unit, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Spain.
Jordi CampsGastrointestinal and Pancreatic Oncology Team, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Spain.
Xiang ZhangDepartment of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, China.
Hongyuan LiDepartment of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, China.
Theodoros FoukakisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Tingxiu XiangKey Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, China.
Jiong WuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, China.
Guosheng RenDepartment of Endocrine and Breast Surgery, The First Affiliated hospital of Chongqing Medical University, Chongqing Medical University, China.
The Affiliated Yongchuan Hospital of Chongqing Medical University · CNShanghai Medical College of Fudan University · CNCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESHospital Clínic de Barcelona · ESKarolinska Institutet · SEKarolinska University Hospital · SEUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER

Indexed as

Breast NeoplasmsBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesteroneendocrine-resistant subgroupER+HER2− breast cancerhistologic gradehypomethylated locimulti-omics

Identifiers

PMID34146382
PMCPMC9208078
OpenAlexW3166144946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.